Neurophysiological Hallmarks of Axonal Degeneration in CIDP Patients: A Pilot Analysis
- PMID: 36358436
- PMCID: PMC9688174
- DOI: 10.3390/brainsci12111510
Neurophysiological Hallmarks of Axonal Degeneration in CIDP Patients: A Pilot Analysis
Abstract
In this work, we aim to identify sensitive neurophysiological biomarkers of axonal degeneration in CIDP patients. A total of 16 CIDP patients, fulfilling the clinical and neurophysiological criteria for typical CIDP, treated with subcutaneous immunoglobulin (ScIg) (0.4 g/kg/week) were evaluated at baseline (before ScIg treatment) and after long-term treatment with ScIg (24 months) by clinical assessment scales, nerve conduction studies (NCS) and electromyography (EMG). Conventional and non-conventional neurophysiological parameters: motor unit potential (MUP) analysis, MUP thickness and size index (SI)] and interference pattern (IP) features were evaluated after long-term treatment (24 months) and compared with a population of 16 healthy controls (HC). An increase of distal motor latency (DML) and reduced compound motor action potential (CMAP) amplitude and area in CIDP patients suggest axonal damage of motor fibers, together with a significant increase of MUP amplitude, duration and area. Analysis of non-conventional MUP parameters shows no difference for MUP thickness; however, in CIDP patients, SI is increased and IP area and amplitude values are lower than HC. Despite clinical and neurophysiological improvement after ScIg treatment, neurophysiological analysis revealed axonal degeneration of motor fibers and motor unit remodeling. Correlation analysis shows that the axonal degeneration process is related to the diagnostic and therapeutic delay. MUP area and SI parameters can detect early signs of axonal degeneration, and their introduction in clinical practice may help to identify patients with the worst outcome.
Keywords: EMG; axonal degeneration; chronic inflammatory demyelinating polyneuropathy; motor unit analysis; subcutaneous immunoglobulin.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.Clin Neurophysiol. 2018 May;129(5):967-973. doi: 10.1016/j.clinph.2018.01.070. Epub 2018 Feb 19. Clin Neurophysiol. 2018. PMID: 29554579
-
Criteria for demyelination based on the maximum slowing due to axonal degeneration, determined after warming in water at 37 degrees C: diagnostic yield in chronic inflammatory demyelinating polyneuropathy.Brain. 2005 Apr;128(Pt 4):880-91. doi: 10.1093/brain/awh375. Epub 2005 Feb 2. Brain. 2005. PMID: 15689367
-
Quantitative muscle ultrasound is useful for evaluating secondary axonal degeneration in chronic inflammatory demyelinating polyneuropathy.Brain Behav. 2017 Sep 15;7(10):e00812. doi: 10.1002/brb3.812. eCollection 2017 Oct. Brain Behav. 2017. PMID: 29075571 Free PMC article.
-
[Physiological approach to peripheral neuropathy. Conventional nerve conduction studies and magnetic motor root stimulation].Rinsho Shinkeigaku. 2004 Nov;44(11):986-90. Rinsho Shinkeigaku. 2004. PMID: 15651350 Review. Japanese.
-
[Electrodiagnostic features in inflammatory demyelinating polyneuropathy].Rinsho Shinkeigaku. 1995 Dec;35(12):1365-7. Rinsho Shinkeigaku. 1995. PMID: 8752397 Review. Japanese.
Cited by
-
Association Between MScanFit Motor Unit Number Estimation and Clinical Function and Response to Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy.J Peripher Nerv Syst. 2025 Mar;30(1):e70001. doi: 10.1111/jns.70001. J Peripher Nerv Syst. 2025. PMID: 39887824 Free PMC article.
-
Parameters Associated with the Required Drug Dose of Intravenous Immunoglobulin in Stable Chronic Inflammatory Demyelinating Polyradiculoneuropathy.Neurol Int. 2023 Mar 10;15(1):405-414. doi: 10.3390/neurolint15010027. Neurol Int. 2023. PMID: 36976670 Free PMC article.
-
Subcutaneous immunoglobulins (SCIG) for chronic inflammatory demyelinating polyneuropathy (CIDP): A comprehensive systematic review of clinical studies and meta-analysis.Neurol Sci. 2024 Nov;45(11):5213-5230. doi: 10.1007/s10072-024-07640-3. Epub 2024 Jun 28. Neurol Sci. 2024. PMID: 38937399 Free PMC article.
References
-
- Kuwabara S., Misawa S. Myelin. Springer Science & Business Media; Berlin, Germany: 2019. Chronic Inflammatory Demyelinating Polyneuropathy; pp. 333–343. - PubMed
-
- Van den Bergh P.Y.K., van Doorn P.A., Hadden R.D.M., Avau B., Vankrunkelsven P., Allen J.A., Attarian S., Blomkwist-Markens P.H., Cornblath D.R., Eftimov F., et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J. Peripher. Nerv. Syst. 2021;26:242–268. doi: 10.1111/jns.12455. - DOI - PubMed
LinkOut - more resources
Full Text Sources